Healthcare Company to Use IBM's Watson AI in Telemedicine App
Source: Streetwise Reports  (10/15/19)
The goal is to reduce the time healthcare workers spend on mundane tasks and thereby improve patient care. More >

Relmada Therapeutics Stock Soars on Phase 2 Depression Study Results
Source: Streetwise Reports  (10/15/19)
Shares of Relmada Therapeutics have traded wildly today after it announced Phase 2 results for its anti-depressant drug dextromethadone. The firm's shares have traded 100–200% higher today and the stock was halted several times trading due to extreme price volatility. More >

Technical Analyst Expects Health Technologies Firm to Break Higher
Source: Clive Maund for Streetwise Reports  (10/14/19)
Technical analyst Clive Maund outlines the reasons this stock might break higher. More >

Cerecor Shares Rise 13% on Sale of Pediatric Portfolio for $32 Million
Source: Streetwise Reports  (10/14/19)
Shares of Cerecor Inc. are trading higher today after reporting that it will sell its pediatric portfolio to Aytu BioScience for $32 million in a combination cash and stock deal. More >

Technical Analyst: As Antibiotic Resistance Rises, So May the Stock of This Livestock Feed Company
Source: Clive Maund for Streetwise Reports  (10/12/19)
Technical analyst Clive Maund believes this stock could gain traction soon. More >

Reata Pharma Shares Trading Higher After Reacquiring U.S. and Worldwide Licensing Rights
Source: Streetwise Reports  (10/11/19)
Shares of Reata Pharmaceuticals are trading 12% higher today after the firm announced it had reacquired all licensing rights in the U.S. for bardoxolone methyl and worldwide rights for omaveloxolone and other next-generation Nrf2 activators from AbbVie. More >

Ra Pharmaceuticals Shares Up 100% Following $2.1 Billion Takeover Bid
Source: Streetwise Reports  (10/10/19)
Shares of Ra Pharmaceuticals doubled today after the firm announced that it will be acquired by Belgian firm UCB for $48 per share in an all cash deal. More >

Soliton Shares Rise on Announcement It Will Report Clinical Data at National Dermatology Conference
Source: Streetwise Reports  (10/9/19)
Soliton Inc. shares traded 10% higher today after advising that later this month it will present the data from clinical trials for its Rapid Acoustic Pulse device used in the treatment of keloid and hypertrophic scars at the American Society for Dermatologic Surgery Annual Meeting. More >

Biopharma Completes Enrollment in Phase 2a Plaque Psoriasis Trial
Source: Streetwise Reports  (10/8/19)
Data from this study should be released by the end of this year. More >

Coverage Initiated on U.S.-Based Precision Therapy Developer
Source: Streetwise Reports  (10/8/19)
The key reasons this story is compelling are given in an H.C. Wainwright & Co. report. More >

JV with Moosehead Breweries Readying Cannabis-Infused Beverages for Commercialization
Source: Streetwise Reports  (10/8/19)
Progress has been made in all areas, from testing the product to evaluating distributors. More >

Healthcare Tech Company Switches to EY Blockchain Platform
Source: Streetwise Reports  (10/7/19)
This will help its customers access the products and tools they need more sustainably. More >

Akcea Therapeutics Inks Worldwide Licensing Deal with Pfizer for Investigative Antisense Therapy, Shares Up 30%
Source: Streetwise Reports  (10/7/19)
Akcea Therapeutics' shares are trading 30% higher today on news that it has entered into a worldwide exclusive licensing agreement with Pfizer for AKCEA-ANGPTL3-LRx used in the treatment of patients with cardiovascular and metabolic diseases. More >

Healthcare Tech Firm Expands Patient Base in Texas
Source: Streetwise Reports  (10/4/19)
The company landed five new U.S. facilities as customers. More >

PDS Biotech Collaborating with Merck in Phase 2 Cancer Trial
Source: Streetwise Reports  (10/3/19)
This morning PDS Biotechnology Corp. shares are trading 38% higher after reporting that it will enter into a clinical collaboration with Merck pairing the firm's PDS0101 with KEYTRUDA for patients with recurrent or metastatic head and neck cancer and high-risk HPV16 infection. More >

Zynex Shares Trade Higher After Reporting a 95% Increase in Q3 Orders
Source: Streetwise Reports  (10/2/19)
Non-invasive medical device maker Zynex Inc's. shares are trading 12% higher on an overall down market day after the company reported that Q3/19 orders are up 95% over the same period in 2018. More >

Phase 2 Data from Potential Multibagger Biopharma 'Checks All the Boxes'
Source: Streetwise Reports  (9/30/19)
The latest clinical trial results are dissected in a ROTH Capital Partners report. More >

U.S. Biotech Rolls Out New Brachytherapy Delivery Tool Used for Prostate Cancer
Source: Streetwise Reports  (9/30/19)
The system, target markets and the marketing campaign for it are discussed in a Dawson James Securities report. More >

Dova Pharma Shares Rise 38% on Swedish Firm Takeover Offer
Source: Streetwise Reports  (9/30/19)
Shares of Dova Pharmaceuticals opened 38% higher today on news that the firm will be acquired by Swedish Orphan Biovitrum. The deal is reportedly valued at $915 million or $29/share. More >

Aravive Shares Rise on Positive Patient Data from Phase 1b Ovarian Cancer Study
Source: Streetwise Reports  (9/27/19)
Shares of Aravive Inc. are trading higher after the firm posted positive data from the initial 12 patients enrolled in the Phase 1b portion of its study of AVB-500 used in the treatment of ovarian cancer. More >

Marinus Pharma Shares Open Up 41% on Phase 2 Epilepsy Trial Results
Source: Streetwise Reports  (9/26/19)
Marinus Pharmaceuticals reported positive top-line results for ganaxolone in its Phase 2 refractory status epilepticus trial with all patients achieving the primary endpoint. More >

Shares Rise as The Medicines Company Reports Positive Topline Results from Two Phase 3 Cholesterol Trials
Source: Streetwise Reports  (9/25/19)
The Medicines Company's shares are trading 8.5% higher today after the firm reported positive results from two phase 3 studies for inclisiran, one for familial hypercholesterolemia, which leads to high levels of LDL-C, and one for atherosclerotic cardiovascular disease. More >

PhaseBio Shares Are on a Tear After Reporting Phase 2a Trial Results
Source: Streetwise Reports  (9/25/19)
The clinical-stage biopharmaceutical stock surged more than 30% Wednesday following a report that PB2452 caused immediate and sustained reversal of ticagrelor in older and elderly subjects. More >

Analyst: Acquisition by Colorado-Based Specialty Pharma 'Could Bolster Revenue 400%'
Source: Streetwise Reports  (9/24/19)
The benefits and terms of the agreement are outlined in a Ladenburg Thalmann report. More >

Ovid Therapeutics Posts Positive Data from Phase 2 Seizure Reduction Trial
Source: Streetwise Reports  (9/24/19)
Ovid Therapeutics' shares are trading 25% higher today after the company reported positive initial data from its ENDYMION soticlestat phase 2 trial for patients with developmental and epileptic encephalopathies. More >